"Comparative gene resequencing in mouse cancer models"

“小鼠癌症模型中的比较基因重测序”

• 批准号: 8165804
• 负责人: David Glenn McFadden
• 金额: $ 17.89万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2016-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8165804
• 关键词: Adenocarcinoma Cell; Affect; Bioinformatics; Cancer Biology; Cancer Model; Cancer Patient; Candidate Disease Gene; Caring; Cell Culture Techniques; Cell Line; Cell Transplantation; Cell physiology; Cessation of life; Code; Comparative Study; Critiques; Cultured Cells; DNA Resequencing; DNA Sequence; DNA copy number; Data; Data Set; Development; Disseminated Malignant Neoplasm; Endocrinology; Engineering; Environment; Evolution; Exhibits; Gene Expression Profile; Genes; Genetic; Genetically Engineered Mouse; Genome; Genomics; Human; Human Cell Line; Hyperplasia; In Vitro; Individual; Internal Medicine; International; Large-Scale Sequencing; Lentivirus Vector; Lung Adenocarcinoma; Malignant Neoplasms; Malignant neoplasm of thyroid; Mediating; Mediator of activation protein; Mentors; Mentorship; Methodology; Modeling; Mus; Mutation; Mutation Spectra; Neoplasm Metastasis; Neoplasms; Oncogenes; Pathway interactions; Phenotype; Play; Point Mutation; Role; Somatic Mutation; Staging; Therapeutic Intervention; Tissue Banking; Tissue Banks; Training; Training Support; Tumor Cell Line; Work; Writing; anticancer research; base; cDNA Expression; cancer cell; cancer genome; cancer genomics; career development; clinical practice; comparative; comparative genomics; exome; genetic technology; human cancer mouse model; improved; in vivo; interest; meetings; mouse model; mutant; new technology; novel; pressure; research study; small hairpin RNA; tumor; tumor initiation; tumor progression; tumorigenesis

DESCRIPTION (provided by applicant): This Career Development proposal will support the training of Dr. David McFadden in mouse cancer models and genomics under the mentorship of Dr. Tyler Jacks with support from collaborators Drs. Meyerson, Hannon, Lander, and Getz. The candidate, Dr. McFadden, is trained in mouse genetics, internal medicine and endocrinology with a clinical practice devoted to the care of thyroid cancer patients. The mentor, Dr. Jacks, is an international leader in cancer research with a focus on the development and use of sophisticated mouse cancer models. Drs. Meyerson, Hannon, Lander, and Getz bring a wealth of expertise in human lung adenocarcinoma genetics, genomics, and bioinformatics. In this unique scientific environment, Dr. McFadden will have the opportunity to train in cancer biology and genomics in order to blend mouse cancer models with cutting edge genetic technology in order to identify novel targets for treatment in human cancer. The development of massively parallel DNA sequencing methodologies has fueled the detailed description of human cancer genomes. However, the functional relevance of specific mutations to the cancer phenotype has been more challenging to define. Carefully constructed mouse models of human cancer have been developed and utilized to carefully characterize all stages of tumorigenesis, including tumor initiation, progression, and metastasis. Although the genetically engineered mutations responsible for tumor induction in these models are known ab initio, the spectrum of mutations acquired during progression from hyperplasia to invasive neoplasm remains largely unknown. Studies have demonstrated that carefully constructed mouse models exhibit gene expression signatures and DNA copy number profiles that overlap with those detected in human cancers, suggesting that the selective pressures exerted on cancer cells are shared between mice and humans. These studies demonstrate the value of cross-species comparisons to identify functionally important driver genes that direct the diverse cellular processes that compose human cancer progression. Over this 5-year proposal, we will generate large-scale sequencing datasets from a mouse model of lung adenocarcinoma to identify the point mutations acquired during tumor evolution. We will perform cross- species comparative studies and pathway analyses to rank candidate genes and pathways of most interest, and precisely characterize the functional role of these alterations using genetically engineered mouse models and human cancer cells. Our preliminary data demonstrate that this approach is feasible. We have generated a murine lung adenocarcinoma tissue bank consisting of advanced, high-grade murine tumors, cell lines, and metastases and developed a hybridization-based enrichment platform for the capture and sequencing of cancer-relevant genes. Using this novel technology, we have sequenced murine lung adenocarcinoma cell lines and identified somatic mutations acquired during tumor progression. PUBLIC HEALTH RELEVANCE: Tumor progression to invasive and metastatic tumors is responsible for most cancer deaths. This study utilizes large-scale DNA sequencing in mouse cancer models and comparative genomics to identify and dissect the functional role of genes that control tumor progression. We anticipate this work will identify new targets for treatment of invasive and metastatic cancers. The written critiques and criteria scores of individual reviewers are provided in essentially unedited form in the "Critique" section below. Please note that these critiques and criteria scores were prepared prior to the meeting and may not have been revised subsequent to any discussions at the review meeting. The "Resume and Summary of Discussion" section above summarizes the final opinions of the committee.

描述(申请人提供)：这份职业发展建议书将支持David McFadden博士在Tyler Jack博士的指导下，在Meyerson博士、Hannon博士、Lander博士和Getz博士的支持下，在老鼠癌症模型和基因组学方面进行培训。候选人麦克法登博士接受过小鼠遗传学、内科医学和内分泌学方面的培训，并致力于甲状腺癌患者的临床实践。这位导师贾克斯博士是癌症研究领域的国际领先者，专注于开发和使用复杂的老鼠癌症模型。Meyerson博士、Hannon博士、Lander博士和Getz博士带来了人类肺腺癌遗传学、基因组学和生物信息学方面的丰富专业知识。在这种独特的科学环境中，麦克法登博士将有机会接受癌症生物学和基因组学方面的培训，以便将小鼠癌症模型与尖端基因技术相结合，从而确定治疗人类癌症的新靶点。大规模并行DNA测序方法的发展推动了对人类癌症基因组的详细描述。然而，定义特定突变与癌症表型的功能相关性更具挑战性。精心构建的人类癌症小鼠模型已被开发并用于仔细描述肿瘤发生的所有阶段，包括肿瘤的起始、进展和转移。虽然在这些模型中导致肿瘤诱导的基因工程突变是已知的从头算，但从增生性肿瘤到侵袭性肿瘤进展过程中获得的突变谱在很大程度上仍然未知。研究表明，精心构建的小鼠模型显示出与人类癌症中检测到的基因表达特征和DNA拷贝数谱重叠的基因表达特征和DNA拷贝数谱，这表明施加在癌细胞上的选择压力在老鼠和人类之间是共同的。这些研究证明了跨物种比较的价值，以确定功能上重要的驱动基因，这些基因指导构成人类癌症进展的不同细胞过程。在这项为期5年的计划中，我们将从肺腺癌的小鼠模型中生成大规模测序数据集，以识别在肿瘤进化过程中获得的点突变。我们将进行跨物种比较研究和通路分析，对最感兴趣的候选基因和通路进行排名，并使用基因工程小鼠模型和人类癌细胞精确表征这些变化的功能作用。初步数据表明，该方法是可行的。我们已经建立了一个由晚期、高级别小鼠肿瘤、细胞系和转移瘤组成的小鼠肺腺癌组织库，并开发了一个基于杂交的浓缩平台，用于捕获和测序癌症相关基因。使用这项新技术，我们已经对小鼠肺腺癌细胞株进行了测序，并鉴定了在肿瘤进展过程中获得的体细胞突变。 公共卫生相关性：肿瘤进展为侵袭性和转移性肿瘤是大多数癌症死亡的原因。这项研究利用小鼠癌症模型中的大规模DNA测序和比较基因组学来识别和剖析控制肿瘤进展的基因的功能作用。我们预计这项工作将为侵袭性和转移性癌症的治疗确定新的靶点。 个别评审员的书面评论和标准分数以基本上未经编辑的形式在下面的“评论”部分提供。请注意，这些批评意见和标准分数是在会议之前准备的，在审查会议上进行任何讨论后可能没有加以修订。上文“恢复和总结讨论”一节概述了委员会的最后意见。